| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6717015 | ALMATICA | Venlafaxine besylate |
Mar, 2023
(1 year, 29 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7776358 | ALMATICA | Extended release venlafaxine besylate tablets |
May, 2028
(4 years from now) | |
Venlafaxine Besylate is owned by Almatica.
Venlafaxine Besylate contains Venlafaxine Besylate.
Venlafaxine Besylate has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Venlafaxine Besylate are:
- US6717015
Venlafaxine Besylate was authorised for market use on 29 June, 2022.
Venlafaxine Besylate is available in tablet, extended release;oral dosage forms.
Venlafaxine Besylate can be used as treatment of depression and generalized anxiety disorder.
The generics of Venlafaxine Besylate are possible to be released after 16 May, 2028.
Drugs and Companies using VENLAFAXINE BESYLATE ingredient
Market Authorisation Date: 29 June, 2022
Treatment: Treatment of depression and generalized anxiety disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
VENLAFAXINE BESYLATE family patents
